← Eichor
Condition: Pan Gene Mutation Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Pan Gene Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Phase 1/Phase 2 · 1 location(s) · Blueprint Medicines Corporation · NCT07629960INTERogating Cancer for Etiology, Prevention and Therapy Navigation
Phase N/A · 3 location(s) · Mayo Clinic · NCT06008392A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
Phase 1/Phase 2 · 32 location(s) · Jacobio Pharmaceuticals Co., Ltd. · NCT06959615JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
Phase 1/Phase 2 · 4 location(s) · Jacobio Pharmaceuticals Co., Ltd. · NCT06973564A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Phase 1 · 23 location(s) · Nested Therapeutics, Inc · NCT06326411Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 15 location(s) · Ensem Therapeutics · NCT06993844Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
Phase 1 · 3 location(s) · Adlai Nortye Biopharma Co., Ltd. · NCT07252479A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral On
Phase 1 · 9 location(s) · Kestrel Therapeutics, Inc. · NCT07458347
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.